Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Marker Therapeutics (MRKR) Net Margin (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Net Margin for 6 consecutive years, with 162.11% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin fell 4226.0% to 162.11% in Q3 2025 year-over-year; TTM through Sep 2025 was 846.98%, a 80965.0% increase, with the full-year FY2024 number at 5365.66%, down 554110.0% from a year prior.
  • Net Margin was 162.11% for Q3 2025 at Marker Therapeutics, up from 479.92% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 826.85% in Q2 2023 to a low of 3542.57% in Q4 2023.
  • A 4-year average of 652.38% and a median of 138.56% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: tumbled -343547bps in 2023, then skyrocketed 363408bps in 2024.
  • Marker Therapeutics' Net Margin stood at 107.1% in 2022, then crashed by -3208bps to 3542.57% in 2023, then skyrocketed by 103bps to 91.5% in 2024, then plummeted by -277bps to 162.11% in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Net Margin are 162.11% (Q3 2025), 479.92% (Q2 2025), and 1273.6% (Q1 2025).